Considering the role of the changed Apo composition in the development of MetS among children after ALL treatment, we believe that this paper, at least partially, highlights the importance of long-term prognosis of the occurrence of metabolic complications that are directly associated with anticancer treatment for hematological malignancies. This evidence concerns the gene AOPEP and hematologic disorder.